 
							₹ 614.49 Cr
2.28%
BSE Healthcare TRI
INF251K01UY7
1000.0
1000.0
500
Mr. Sanjay Chawla
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) | 
|---|---|---|---|
| Baroda BNP Paribas Health and Wellness Fund Regular Growth | - | - | - | 
| Benchmark | - | - | - | 
Equity
Debt
Others
The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns. However, there can be no assurance that the investment objective of the Scheme will be realized.
| Company | Holdings (%) | 
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 10.64 | 
| Clearing Corporation of India Ltd | 7.88 | 
| DIVIS LABORATORIES LIMITED EQ NEW RS. 2/- | 7.64 | 
| MANKIND PHARMA LIMITED EQ NEW FV RE. 1/- | 7.53 | 
| APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/- | 6.03 | 
| CIPLA LIMITED EQ NEW FV RS.2/- | 5.44 | 
| MAX HEALTHCARE INSTITUTE LIMITED EQ | 5.44 | 
| ABBOTT INDIA LIMITED EQ | 4.29 | 
| ASTER DM HEALTHCARE LIMITED EQ | 4.08 | 
| TORRENT PHARMACEUTICALS LIMITED EQ NEW FV RS.5/- | 3.81 | 
| Sector | Holdings (%) | 
|---|---|
| Healthcare | 90.54 | 
| Financial Services | 2.81 | 
| Consumer Services | 1.42 |